X Bioscience PCL (BKK:XBIO)
Thailand
· Delayed Price · Currency is THB 0.1100
0.00 (0.00%)
Last updated: Apr 22, 2025
X Bioscience PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 319.24 | 311.77 | 344.49 | 254.04 | 415.62 | Upgrade
|
| Revenue Growth (YoY) | 2.40% | -9.50% | 35.60% | -38.88% | -2.13% | Upgrade
|
| Cost of Revenue | 180.63 | 159.67 | 172.3 | 126.82 | 285.99 | Upgrade
|
| Gross Profit | 138.61 | 152.11 | 172.18 | 127.23 | 129.62 | Upgrade
|
| Selling, General & Admin | 389.82 | 272.53 | 455.41 | 227.79 | 264.32 | Upgrade
|
| Operating Expenses | 389.82 | 272.53 | 455.41 | 227.79 | 261.26 | Upgrade
|
| Operating Income | -251.21 | -120.43 | -283.23 | -100.56 | -131.63 | Upgrade
|
| Interest Expense | -34.29 | -39.94 | -56.52 | -14.45 | -16.58 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.01 | 0.14 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 7.18 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.58 | 11.72 | 3.33 | 9.45 | 4.13 | Upgrade
|
| EBT Excluding Unusual Items | -277.92 | -148.65 | -336.41 | -105.55 | -136.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -119.79 | Upgrade
|
| Asset Writedown | - | - | - | - | 22.14 | Upgrade
|
| Pretax Income | -277.92 | -148.65 | -336.41 | -105.55 | -234.41 | Upgrade
|
| Income Tax Expense | -15.84 | -1.13 | -5.65 | -5.65 | 2.72 | Upgrade
|
| Earnings From Continuing Operations | -262.07 | -147.52 | -330.77 | -99.9 | -237.13 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -245.22 | -176.55 | - | Upgrade
|
| Net Income to Company | -262.07 | -147.52 | -575.99 | -276.45 | -237.13 | Upgrade
|
| Minority Interest in Earnings | 1.85 | - | - | - | -1.68 | Upgrade
|
| Net Income | -260.22 | -147.52 | -575.99 | -276.45 | -238.81 | Upgrade
|
| Net Income to Common | -260.22 | -147.52 | -575.99 | -276.45 | -238.81 | Upgrade
|
| Shares Outstanding (Basic) | 1,289 | 877 | 814 | 814 | 679 | Upgrade
|
| Shares Outstanding (Diluted) | 1,289 | 877 | 814 | 814 | 679 | Upgrade
|
| Shares Change (YoY) | 46.88% | 7.78% | - | 19.79% | -6.86% | Upgrade
|
| EPS (Basic) | -0.20 | -0.17 | -0.71 | -0.34 | -0.35 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.17 | -0.71 | -0.34 | -0.35 | Upgrade
|
| Free Cash Flow | -73.77 | -133.59 | -291.22 | -212.57 | -67.58 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.15 | -0.36 | -0.26 | -0.10 | Upgrade
|
| Gross Margin | 43.42% | 48.79% | 49.98% | 50.08% | 31.19% | Upgrade
|
| Operating Margin | -78.69% | -38.63% | -82.22% | -39.58% | -31.67% | Upgrade
|
| Profit Margin | -81.51% | -47.32% | -167.20% | -108.82% | -57.46% | Upgrade
|
| Free Cash Flow Margin | -23.11% | -42.85% | -84.54% | -83.67% | -16.26% | Upgrade
|
| EBITDA | -224.53 | -102.69 | -189.44 | -13.51 | -65.57 | Upgrade
|
| EBITDA Margin | -70.33% | -32.94% | -54.99% | -5.32% | -15.78% | Upgrade
|
| D&A For EBITDA | 26.68 | 17.73 | 93.79 | 87.05 | 66.06 | Upgrade
|
| EBIT | -251.21 | -120.43 | -283.23 | -100.56 | -131.63 | Upgrade
|
| EBIT Margin | -78.69% | -38.63% | -82.22% | -39.58% | -31.67% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.